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fractions. Treatments were planned on Eclipse software (Varian 
Medical Systems, Inc) using 7-9 static fields or two volumetric 
modulated arcs for delivery on Varian linacs. Kilovoltage free 
breathing CBCTs were taken both for initial patient positioning 
and also immediately after treatment. The pre- and post-
treatment CBCTs were compared to confirm that the lung tumour 
remained inside the PTV and to assess the stability and the 
suitability of the PTV margin used. Comparisons were performed 
using a visual match by at least two experienced professionals in 
Varian’s Offline Review software. The time interval between 
both CBCTs was extracted trying to have a measure of the 
treatment time. 
Results: There were 44 cases/treatments with pre- and post-
treatment CBCTs reviewed. The mean time between the CBCTs 
(treatment time) was 16.5 ± 6 minutes (range: 10 to 34 minutes). 
In all cases the tumour was appropriately kept inside the PTV in 
the post-treatment CBCT. The mean corrections between pre 
and post-treatment CBCTs were -0.7 ± 1.6 mm (range -5.0 to 3.0 
mm) vertically, -0.3 ± 1.7 mm (range -4.8 to 3.0 mm) 
longitudinally, and -0.4 ± 1.5 mm (range -4.0 to 2.0 mm) 
laterally. 
Conclusions: There was no tumour displaced outside the PTV 
even during relatively slow SBRT delivery in all our lung cancer 
patients treated with SBRT without any customized 
immobilization. For our cohort of patients, the PTV margin (5 
mm) used was consistent with the measured residual intra-
fraction motion, also reported in other studies. This experience 
goes along with the growing trend in frameless, free-breathing 
SBRT for lung tumours. 
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Purpose: Obtaining a proper specimen for diagnostic pathology 
and genetic analysis can be challenging in some patients. The 
purpose of this study was to examine the diagnostic yield for 
different specimen types submitted for epidermal growth factor 
receptor (EGFR) mutation testing in patients with metastatic 
non-small cell lung cancer (NSCLC). 
Methods and Materials: A multicentre retrospective study was 
conducted of patients with a pathologic diagnosis of metastatic, 
non-squamous, NSCLC for the period 2010 to 2012. Patients were 
identified using a provincial cancer registry. Data was collected 
on patient characteristics, biopsy characteristics, and diagnostic 
outcome. All EGFR testing was done at a central lab for exon 19 
deletions and exon 21 mutations. 
Results: For 1499 patients, the pathologic diagnosis was 
determined from histology in 945 and cytology in 554. Six 
hundred twenty-seven (41.8%) of these patients had EGFR 
mutation testing. Mutation testing was requested in a higher 
proportion of patients with histology compared to those with 
cytology, 48.6% (459/945) versus 30.3% (168/554), respectively 
(p < 0.001). In patients with histology the diagnostic yield was 
88.2% (19.8% EGFR+; 68.4% EGFR wild type (WT); 11.8% non-
diagnostic). In patients with cytology the diagnostic yield was 
82.1% (17.9% EGFR+; 64.3% EGFR WT; 17.9% non-diagnostic). 
There was no statistically significant difference in diagnostic 
yield (p = 0.063) or mutation rates (p = 0.86) between the two 
specimen types. The histology and cytology cohorts were no 
different for age (p = 0.10), ECOG performance status (p = 0.39), 
and gender (p = 0.24). By location, specimens were obtained 
from the primary tumour in 317 (50.6%), thoracic lymph node in 
87 (13.9%), metastatic site in 158 (25.2%), and pleura/pleural 
fluid in 65 (10.4%). The diagnostic yields from these sites were 
84%, 87%, 91%, and 97%, respectively. 
Conclusions: For EGFR mutation testing, oncologists should not 
feel limited by biopsy site or specimen type. Cytology is 
sufficient for testing in most patients, and the diagnostic yield is 
comparable to histology. 
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Purpose: Miliary metastases arise from widespread 
hematogenous disease dissemination and are characterized by 
metastatic nodules that are diffuse, innumerable and small. The 
purpose of this study was to examine the incidence, prognostic 
significance, and impact of epidermal growth factor receptor 
(EGFR) mutations for miliary metastases from non-small cell lung 
cancer (NSCLC). 
Methods and Materials: Patients were identified from a 
Provincial cancer registry (British Columbia, Canada) for the 
period 2010-2012. Inclusion criteria were Stage IV NSCLC at 
initial presentation and conclusive EGFR mutation testing (for 
exons 19 and 21). Miliary metastases for each organ site were 
objectively defined as > 15 metastatic nodules of < 1 cm 
diameter size involving more than one organ lobe and bilaterally 
distributed. The primary endpoint was the association between 
EGFR mutations and miliary lung, brain, and liver metastases. 
The significance of EGFR mutation status and miliary metastases 
on survival were assessed using the Cox proportional hazards 
model. 
Results: For 543 patients, 422 (77.7%) were EGFR wild type (WT) 
and 121 (22.3%) EGFR mutation positive (EGFR+). Six (1.1%) 
patients had miliary brain metastases: two (0.5%) EGFR WT and 
four (3.3%) EGFR+ (exon 19 = 4; exon 21 = 0). Patients with an 
exon 19 mutation had a significantly higher incidence of miliary 
brain metastases compared to EGFR WT (p = 0.005). Twenty-nine 
(5.3%) patients had miliary lung metastases: 15 (3.6%) EGFR WT 
and 14 (11.6%) EGFR+ (exon 19 = 8; exon 21 = 6). Patients with 
EGFR+ status had a significantly higher incidence of miliary lung 
metastases compared to EGFR WT (p = 0.002). There was no 
difference in miliary lung metastases between exon subtypes (p 
= 0.78). Two (0.4%) patients had miliary liver metastases: two 
(0.5%) EGFR WT and none EGFR+. In multivariate analysis (MVA), 
miliary (versus non-miliary) brain (p = 0.47) and lung (p = 0.64) 
metastases were not significant factors for survival. EGFR+ status 
was significant for longer survival (p = 0.001) in MVA. 
Conclusions: Mutations in EGFR predispose to miliary brain and 
lung metastases. The survival outcome of patients with military 
brain and lung metastases is not adverse compared to non-
miliary metastases. 
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Purpose:  One of the purported advantages of SABR as an 
alternative treatment option to surgery for early-stage non-small 
cell lung cancer (ES-NSCLC) is health-related quality of life 
(HRQOL). The purpose of this study is to 1) perform a systematic 
review of HRQOL following SABR for ES-NSCLC and 2) to describe 
HRQOL and indirect costing outcomes from the ROSEL 
randomized trial comparing surgery and SABR for ES-NSCLC. 
Methods and Materials:  In ROSEL, 22 patients with ES-NSCLC 
were randomized to SABR or surgery before the trial closed due 
to poor accrual. HRQOL was evaluated at baseline, and then 
three, six, 12, 18, and 24 months post-treatment using the 30 
